Systems Biology Analysis of Kinase Inhibitor Protein Target Profiles in Leukemia Treatments

  • Jacques Colinge
  • Uwe Rix
  • Keiryn L. Bennett
  • Giulio Superti-Furga
Part of the Lecture Notes in Computer Science book series (LNCS, volume 7223)

Abstract

To be able to understand the mechanisms of action of drugs, predict their efficacy, and anticipate their potential side-effects is important during drug development. In diseases where the genetic background of patients modulates treatment response, it might allow personalizing the therapy.

Substantial progress in proteomic technologies[1] have made it possible to develop chemical proteomics methods, where the protein targets of a drug are affinity-purified and identified by mass spectrometry[2, 3]. Compound-protein interactions are measured in a biological context as opposed to in vitro binding assays. That is, drugprotein interactions can not only be determined proteome-wide, but also in a tissue- or cell type-dependent manner.

Keywords

Chronic Myeloid Leukemia Noonan Syndrome Target Spectrum Vitro Binding Assay Human Interactome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Domon, B., Aebersold, R.: Mass spectrometry and protein analysis. Science 312, 212–217 (2006)CrossRefGoogle Scholar
  2. 2.
    Bantscheff, M., Scholten, A., Heck, A.J.: Revealing promiscuous drug-target interactions by chemical proteomics. Drug Discov. Today 14, 1021–1029 (2009)CrossRefGoogle Scholar
  3. 3.
    Rix, U., Superti-Furga, G.: Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616–624 (2009)CrossRefGoogle Scholar
  4. 4.
    Araujo, R.P., Liotta, L.A., Petricoin, E.F.: Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat. Rev. Drug Discov. 6, 871–880 (2007)CrossRefGoogle Scholar
  5. 5.
    Keith, C.T., Borisy, A.A., Stockwell, B.R.: Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71–78 (2005)CrossRefGoogle Scholar
  6. 6.
    Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L.L., Planyavsky, M., Fernbach, N.V., Kaupe, I., Bennett, K.L., Valent, P., Colinge, J., Kocher, T., Superti-Furga, G.: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055–4063 (2007)CrossRefGoogle Scholar
  7. 7.
    Kohler, S., Bauer, S., Horn, D., Robinson, P.N.: Walking the interactome for prioritization of candidate disease genes. Am. J. Hum. Genet. 82, 949–958 (2008)CrossRefGoogle Scholar
  8. 8.
    Colinge, J., Rix, U., Superti-Furga, G.: Novel global network scores to analyze kinase inhibitor profiles. In: Chen, L., Zhang, X., Shen, B., Wu, L., Wang, Y. (eds.) 4th International Conference on Computational Systems Biology, vol. 13, pp. 305–313. World Publishing Company, Suzhou (2010)Google Scholar
  9. 9.
    Colinge, J., Rix, U., Bennett, K.L., Superti-Furga, G.: Systems biology analysis of protein-drug interactions. Proteomics Clin. Appl. (in press)Google Scholar
  10. 10.
    Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K.L., Gao, J., Song, L., Eschrich, S., Superti-Furga, G., Koomen, J., Haura, E.B.: A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 6, 291–299 (2010)CrossRefGoogle Scholar
  11. 11.
    Gelb, B.D., Tartaglia, M.: Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum. Mol. Genet. 15 Spec No 2, R220-226 (2006)Google Scholar
  12. 12.
    Mullighan, C.G., Miller, C.B., Radtke, I., Phillips, L.A., Dalton, J., Ma, J., White, D., Hughes, T.P., Le Beau, M.M., Pui, C.H., Relling, M.V., Shurtleff, S.A., Downing, J.R.: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Jacques Colinge
    • 1
  • Uwe Rix
    • 1
  • Keiryn L. Bennett
    • 1
  • Giulio Superti-Furga
    • 1
  1. 1.Center for Molecular Medicine of the Austrian Academy of Sciences AKH-BT 25.3ViennaAustria

Personalised recommendations